Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Rating) was the target of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 754,400 shares, a decline of 59.9% from the April 30th total of 1,880,000 shares. Based on an average daily volume of 2,840,000 shares, the days-to-cover ratio is currently 0.3 days.
Panbela Therapeutics Trading Down 6.6 %
Shares of NASDAQ:PBLA traded down $0.02 on Friday, hitting $0.34. 682,261 shares of the company’s stock were exchanged, compared to its average volume of 2,661,840. Panbela Therapeutics has a 12 month low of $0.32 and a 12 month high of $64.40. The stock has a market capitalization of $5.64 million, a price-to-earnings ratio of 0.00 and a beta of 2.03. The business’s 50 day simple moving average is $0.45 and its two-hundred day simple moving average is $0.68. The company has a debt-to-equity ratio of 1.65, a current ratio of 0.80 and a quick ratio of 0.80.
Panbela Therapeutics (NASDAQ:PBLA – Get Rating) last released its quarterly earnings data on Thursday, March 16th. The company reported ($5.68) earnings per share for the quarter. Analysts anticipate that Panbela Therapeutics will post -1.4 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. Armistice Capital LLC acquired a new stake in Panbela Therapeutics in the 3rd quarter valued at about $588,000. Sabby Management LLC acquired a new stake in Panbela Therapeutics in the 1st quarter valued at about $189,000. CVI Holdings LLC acquired a new stake in Panbela Therapeutics in the 1st quarter valued at about $175,000. Hudson Bay Capital Management LP acquired a new stake in Panbela Therapeutics in the 1st quarter valued at about $157,000. Finally, Altium Capital Management LP acquired a new stake in shares of Panbela Therapeutics during the 1st quarter worth about $148,000. 9.37% of the stock is owned by institutional investors and hedge funds.
About Panbela Therapeutics
Panbela Therapeutics, Inc engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types.
- Get a free copy of the StockNews.com research report on Panbela Therapeutics (PBLA)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.